Navigating the Interplay of Accountability and Authority in Biotech Project Management

When biotech and pharma projects stall, go over budget, or collapse entirely, the root cause is rarely purely technical — it's almost always structural. One of the most consistent structural failures is a misalignment between authority and accountability: people are held accountable for outcomes they don't have the power to influence, or given power without the ownership that should come with it. This misalignment is especially consequential in life sciences, biotech, and pharma, where cross-functional teams spanning R&D, clinical operations, regulatory affairs, CMC, and commercial must coordinate under intense time and cost pressure.

The Project Management Body of Knowledge (PMBOK) Guide frames project success not just around delivering outputs, but around enabling value — and that value is only possible when the right people have both the mandate and the means to act. This post breaks down the authority-accountability relationship, why it is structurally complex in biotech and pharma, and what organizations can do to get it right.

Project manager analyzing project timeline and tasks

Defining the Core Concepts — Accountability, Responsibility, and Authority

These three terms are often used interchangeably in practice, but they are meaningfully distinct — and confusing them is one of the primary drivers of project dysfunction.

• Accountability means being answerable for the outcome of a task or project. It cannot be delegated — even when work is distributed across a team, the accountable individual remains the one who must own and explain the result.

• Responsibility is the obligation to execute a specific task or deliverable. It can be delegated, and delegation transfers ownership of the execution, but not the final accountability for the outcome.

• Authority is the formal or delegated power to make decisions, direct resources, and enforce action within defined limits — it is what enables an accountable person to actually influence outcomes.

  
  

The PMBOK is explicit that the project manager must have sufficient authority over the project team, budget, and schedule to fulfill their accountability. Where that authority is limited or unclear, project performance suffers — not because of individual failure, but because of structural misalignment. The critical takeaway: accountability without authority is structurally unfair and operationally dangerous, and in biotech and pharma, it is more common than most organizations acknowledge.

Why This Is Especially Complex in Biotech and Pharma

The life sciences industry has a uniquely fragmented authority landscape, shaped by organizational structure, regulatory requirements, and the inherently cross-functional nature of drug development. In small biopharma companies, which tend to operate as functional or weak matrix organizations, the project manager's role is often more coordinator than true decision-maker — with limited authority over resources or budget and a heavy reliance on influence rather than formal power. In contrast, the majority of mid-to-large pharma and biotech companies operate as strong matrix organizations, where project managers have considerably more authority and access to dedicated project staff — but even here, the balance varies widely depending on company culture and governance maturity (link).

Large legacy pharma organizations have historically struggled with siloed structures where therapeutic, geographic, and functional areas operated in organizational and cultural isolation, creating slow and diffuse decision-making where accountability was blurred across multiple levels. In contrast, emerging biotech companies tend to push decision-making downward, with more direct accountability and a flatter, more communicative structure. The regulatory environment adds another layer of complexity: accountability for GxP compliance, data integrity, and regulatory submissions must be clearly assigned and formally documented — ambiguity here creates not just operational inefficiency, but real legal and regulatory exposure. In CRO-sponsor relationships, accountability becomes bilateral — the technical team must remain accountable for project success, while the sponsor must be accountable for providing resources and financial support, and when either side fails to honor that obligation, the project is at risk (link).

The Project Manager at the Center of This Dynamic

The project manager is the individual most directly affected by the authority-accountability relationship — they are invariably accountable for project outcomes but frequently operate with constrained or negotiated authority. According to the PMBOK, the PM is accountable for delivering the project within scope, time, cost, and quality constraints — a mandate that requires real authority to fulfill. In practice, PM authority is shaped by organizational structure: in functional organizations, the PM may negotiate with department heads for resources with little formal leverage, while in projectized organizations, the PM typically has full control over the team and budget.

Regardless of structure, effective project managers in life sciences build authority through trust and credibility, not just org charts — they negotiate, influence, and communicate to extend their functional reach beyond their formal mandate. A strong governance structure with clear escalation paths is essential in this environment, enabling timely resolution of issues before they become project-threatening and giving the PM a defined channel to escalate when their authority is insufficient to meet their accountability (link). The project charter is the foundational mechanism for establishing PM authority — the PMBOK identifies it as the document by which the project manager is formally authorized to apply resources to project activities, and a poorly scoped charter creates authority gaps from day one.

Tools and Frameworks for Aligning Authority and Accountability

The most effective way to prevent authority-accountability misalignment is to make roles explicit at the outset — ambiguity compounds over time and becomes increasingly difficult to resolve mid-project. Several tools are essential for doing this well:

• RACI Matrix (Responsible, Accountable, Consulted, Informed) — the most widely used tool for documenting role clarity; the critical discipline is ensuring that every deliverable has exactly one "A" — one person who is accountable — and that this person has the organizational authority to actually ensure the work gets done; a common failure is assigning accountability to someone without the power to enforce the outcome

• Project Charter — the document that formally establishes the PM's authority to apply resources to the project; without a well-drafted charter, authority gaps are baked in from initiation

• Responsibility Assignment Matrix (RAM) — used to connect the Work Breakdown Structure (WBS) to team members at the task level, ensuring accountability is mapped and traceable throughout execution

• Decision Rights Documentation — explicitly stating who has authority to make which categories of decisions (resource allocation, timeline changes, budget approvals, regulatory strategy) eliminates the gray zones where authority-accountability mismatches thrive most

• Governance Frameworks — in larger organizations, Enterprise Project Management Offices (EPMOs) play a critical role in standardizing how authority is defined and delegated across the project portfolio, creating consistency and visibility across programs

  
  

A pharmaceutical company implementing a new quality management system used weekly "role clarity sessions" where teams reviewed their RACI matrices together and addressed confusion in real time — this practice significantly reduced implementation delays and improved adoption of the change (link). This kind of structured, recurring role review is a best practice applicable across biotech and pharma project types.

Common Failure Modes — And What They Look Like in Life Sciences

Even organizations with strong PM practices fall into predictable traps when it comes to authority and accountability alignment.

• Micromanagement occurs when senior leaders retain decision-making authority while holding others accountable for outcomes those others cannot control — in pharma, this often manifests as executives approving every budget line while expecting PMs to deliver on aggressive timelines.

• Accountability diffusion is common in highly cross-functional drug development teams, where accountability is spread across so many parties — R&D, clinical, regulatory, CMC, commercial — that no single person is clearly answerable for overall outcomes; this is especially dangerous at stage-gate reviews where investment decisions hinge on clear ownership.

Delegation without empowerment happens when responsibility is handed down without the authority, resources, or decision rights to fulfill it — as one business leader put it, "accountability without authority or resources is a recipe for failure" (link). Organizational silos, a persistent challenge in large pharma, create accountability gaps at the exact interfaces between functions where the most complex drug development challenges live — the handoffs between discovery and development, between clinical and regulatory, between technical operations and commercial.

Building an Accountability-First Culture

Structural tools like RACI matrices and project charters are necessary but not sufficient — authority and accountability must also be embedded in organizational culture to be durable. Leadership must model accountability before expecting it from teams; organizations where management adopts a genuine ownership mindset see faster decision-making, more empowered teams, and accelerated milestone achievement (link). Psychological safety is a prerequisite: teams that fear blame will avoid taking on accountability, creating a culture where ownership is constantly deflected — particularly damaging in pharma, where early identification of problems is critical to avoiding costly late-stage failures.

Regular retrospectives and project reviews that examine not just what went wrong technically but who had the authority to act and whether they had it in time create the feedback loop necessary for continuous improvement. The PM's role extends to actively managing the authority-accountability ecosystem on their projects — surfacing misalignments proactively, escalating to sponsors when authority is insufficient, and advocating for the structural clarity that lets their team perform.

Conclusion / Call to Action

In biotech and pharma, where projects are complex, cross-functional, high-stakes, and expensive, authority-accountability misalignment is not a soft organizational problem — it is a direct threat to project success and ultimately to patient outcomes. The solution is not to give everyone more authority or more accountability in isolation — it is to ensure these two things are precisely matched at every level of the project hierarchy, established clearly at initiation, and actively maintained throughout the project lifecycle. At Ganvion Biotech Solutions, we help life sciences organizations diagnose and resolve authority-accountability gaps, structure project teams for clarity and performance, and build the governance frameworks that keep complex, multi-functional projects on track from initiation through closeout.